抗磷脂酶A2受体抗体在原发性膜性肾病患者中的研究进展

doi:10.3969/j.issn.1004-583X.2021.06.019

摘要/Abstract

摘要：

膜性肾病是成人肾病综合征的常见病因之一,大约75%的膜性肾病为原发性,其他病因包括自身免疫性疾病、感染、药物和恶性肿瘤等。血清抗磷脂酶A2受体(PLA2R)抗体被认为是原发性膜性肾病的血清学诊断的生物标记物,并且该抗体与原发性膜性肾病的诊断、疾病活动、治疗效果、病情评估等密切相关,但国内外研究显示PMN中抗PLA2R抗体阳性率存在差异,以及特异性方面存在疑惑,值得进一步探讨。本文就抗PLA2R抗体与PMN的研究进展作一综述。

关键词: 肾小球肾炎, 膜性, 受体, 磷脂酶A2, 诊断, 鉴别

中图分类号:

R692.31

刘一坤, 刘冰, 冯珍. 抗磷脂酶A2受体抗体在原发性膜性肾病患者中的研究进展[J]. 临床荟萃, 2021, 36(6): 569-573.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://lchc.magtechjournal.com/CN/10.3969/j.issn.1004-583X.2021.06.019

https://lchc.magtechjournal.com/CN/Y2021/V36/I6/569

参考文献 38

[1]	张明超, 经艳, 郑男君, 等. 肾组织PLA2R抗原检测方法的建立和评估[J]. 中华肾脏病杂志, 2018, 34(5):385-386.
[2]	Ronco P, Debiec H. Anti-phospho1ipase A2 receptor antibodies and the pathogenesis of membranous nephropathy[J]. Nephron Clin Pract, 2014, 128(3/4):232-237. doi: 10.1159/000368588 URL
[3]	Beck LH, Bonegio RGB, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy[J]. N Engl J Med, 2009, 361(1):11-21. doi: 10.1056/NEJMoa0810457 URL
[4]	方玲, 顾向明, 周泽红, 等. 两种方法检测血清抗磷脂酶A2受体抗体在膜性肾病中的应用分析[J]. 检验医学与临床, 2017, 14(15):2196-2198.
[5]	Corrado M, Maurizio B, Giovanni C, et al. Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy[J]. Clin J Am Soc Nephrol, 2012, 7(9):1-7. doi: 10.2215/CJN.12121111 URL
[6]	Zhang D, Zou J, Zhang C, et al. Clinical and histological features of phospholipase A2 receptor-associated and thrombospondin type-I domain-containing 7A-associated idiopathic membranous nephropathy: A single center retrospective study from China[J]. Med Sci Monit, 2018, 24(1):5076-5083. doi: 10.12659/MSM.909815 URL
[7]	Wang J, Cui Z, Lu J, et al. Circulating antibodies against thrombospondin type-I domain-containing 7A in Chinese patients with idiopathic membranous nephropathy[J]. Clin J Am Soc Nephrol, 2017, 12(10):1-10. doi: 10.2215/CJN.11511116 URL
[8]	Vincenzo LI, Federico P, Alberto SR, et al. Routine immunohistochemical staining in membranous nephropathy: In situ detection of phospholipase A2 receptor and thrombospondin type 1 containing 7A domain[J]. J Nephrol, 2018, 31(4):543-550. doi: 10.1007/s40620-018-0489-z URL
[9]	王述莲, 孙钧, 郑继伟, 等. 抗磷脂酶A2受体抗体表达在特发性膜性肾病人肾组织及血液中的检测价值[J]. 实用医学杂志, 2016, 32(3):434-436.
[10]	詹富国, 吴秀风, 许文燊, 等. 血清抗磷脂酶A2受体抗体在特发性膜性肾病中的诊断价值[J]. 中国卫生标准管理, 2017, 8(18):110-111.
[11]	Radice A, Pieruzzi F, Trezzi B, et al. Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases[J]. J Nephrol, 2018, 31(2):271-278. doi: 10.1007/s40620-017-0451-5 pmid: 29081027
[12]	Garcia-Vives E, Solé C, Moliné T, et al. Antibodies to M-type phospholipase A2 receptor (PLA2R) in membranous lupus nephritis[J]. Lupus, 2019, 28(3):1-10.
[13]	许向青, 朱雪婧, 袁曙光, 等. M型磷脂酶A2受体及其抗体在乙肝病毒相关性膜性肾病中的临床意义[J]. 中南大学学报(医学版), 2016, 41(10):1064-1068.
[14]	Tian C, Li L, Liu T, et al. Circulating antibodies against M-type phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A in Chinese patients with membranous nephropathy[J]. Int Urol Nephrol, 2019, 51(8):1371-1377. doi: 10.1007/s11255-019-02146-w URL
[15]	蒋真斌, 蔡美顺, 董葆, 等. 适合中国人的抗磷脂酶A2受体抗体临界值的界定[J]. 中华肾脏病杂志, 2020, 36(5):379-384.
[16]	计蕾, 余慰, 钟雪. 特发性膜性肾病患者血清抗磷脂酶A2受体抗体与尿中IgG4检测的临床意义[J]. 中国免疫学杂志, 2018, 34(7):1050-1053+1058.
[17]	Huang B, Zhang Y, Wang L, et al. Phospholipase A2 receptor antibody IgG4 subclass improves sensitivity and specificity in the diagnosis of idiopathic membranous nephropathy[J]. Kidney Blood Press Res, 2019, 44(4):1-10. doi: 10.1159/000497806 URL
[18]	Wang Y, He YX, Diao TT, et al. Urine anti-PLA2R antibody is a novel biomarker of idiopathic membranous nephropathy[J]. Oncotarget, 2018, 9(1):67-74. doi: 10.18632/oncotarget.19859 pmid: 29416596
[19]	詹富国, 吴秀风, 陈惠娟, 等. 三种实验室指标在膜性肾病中的诊断价值[J]. 中国卫生标准管理, 2017, 8(19):124-126.
[20]	Pang L, Zhang AM, Li HX, et al. Serum anti-PLA2R antibody and glomerular PLA2R deposition in Chinese patients with membranous nephropathy: A cross-sectional study[J]. Medicine, 2017, 96(24):1-7.
[21]	Li C, Li H, Wen YB, et al. Analysis of predictive factors for immunosuppressive response in antiphospholipase A2 receptor antibody positive membranous nephropathy[J]. BMC Nephrol, 2018, 19(1):1-6. doi: 10.1186/s12882-017-0808-y URL
[22]	林伟锋, 李航, 李雪梅, 等. 抗磷脂酶A2受体抗体与特发性膜性肾病的关系[J]. 中华内科杂志, 2015, 54(9):783-788.
[23]	Han WW, Tang LJ, Kong XL, et al. Clinical significance of autoantibodies in the assessment and treatment of idiopathic membranous nephropathy[J]. Exp Ther Med, 2019, 17(3):1825-1830.
[24]	Zhang Q, Huang B, Liu X, et al. Ultrasensitive quantitation of anti-phospholipase A2 receptor antibody as a diagnostic and prognostic indicator of idiopathic membranous nephropathy[J]. Sci Rep, 2017, 7(1):12049. doi: 10.1038/s41598-017-12014-1 URL
[25]	Wu X, Liu L, Guo Y, et al. Clinical value of a serum anti-PLA2R antibody in the diagnosis and monitoring of primary membranous nephropathy in adults[J]. Int J Nephrol Renovasc Dis, 2018, 11:241-247. doi: 10.2147/IJNRD URL
[26]	Kim YG, Choi YW, Kim SY, et al. Anti-phospholipase A2 receptor antibody as prognostic indicator in idiopathic membranous nephropathy[J]. Am J Nephrol, 2015, 42(3):250-257. doi: 10.1159/000440983 URL
[27]	褚晓鑫, 徐秀, 何晓峰, 等. 血清抗磷脂酶A2受体抗体在特发性膜性肾病缓解中的价值[J]. 2018(10):752-758.
[28]	Provatopoulou S, Kalavrizioti D, Stangou M, et al. Circulating anti-phospholipase A2 receptor antibodies as a diagnostic and prognostic marker in Greek patients with idiopathic membranous nephropathy - a retrospective cohort study[J]. Rom J Intern Med, 2018, 57(2):141-150.
[29]	Guo N, Cao Y, Dai H, et al. Anti-phospholipase A2 receptor (Anti-PLA2R) antibody in diagnosis and treatment of idiopathic membranous nephropathy: A single-center observational study in China[J]. Med Sci Monit, 2019, 25:9364-9368. doi: 10.12659/MSM.917732 URL
[30]	Pourcine F, Dahan K, Mihout F, et al. Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years[J]. PLoS One, 2017, 12(3):e0173201. doi: 10.1371/journal.pone.0173201 URL
[31]	Jung OY, Hee YS, Ki KD, et al. Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy[J]. PLoS One, 2013, 8(4):e62151. doi: 10.1371/journal.pone.0062151 URL
[32]	Dong D, Fan TT, Wang YY, et al. Relationship between renal tissues phospholipase A2 receptor and its serum antibody and clinical condition and prognosis of idiopathic membranous nephropathy: a meta-analysis[J]. BMC Nephrol, 2019, 20(1):444. doi: 10.1186/s12882-019-1638-x pmid: 31791262
[33]	Liang Y, Wan J, Chen Y, et al. Serum anti-phospholipase A2 receptor (PLA2R) antibody detected at diagnosis as a predictor for clinical remission in patients with primary membranous nephropathy: A meta-analysis[J]. BMC Nephrol, 2019, 20(1):360. doi: 10.1186/s12882-019-1544-2 URL
[34]	Qu Z, Zhang MF, Cui Z, et al. Antibodies against M-type phospholipase A2 receptor may predict treatment response and outcome in membranous nephropathy[J]. Am J Nephrol, 2018, 48(6):1-9. doi: 10.1159/000490625 URL
[35]	Joo SE, Hwa JK, Ae YY, et al. Anti-phospholipase A2 receptor antibody as a prognostic marker in patients with primary membranous nephropathy[J]. Kidney Res Clin Pract, 2018, 37(3):248-256. doi: 10.23876/j.krcp.2018.37.3.248 URL
[36]	Hirotaka M, Ken Y, Hirofumi N, et al. Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes[J]. Ann Rheum Dis, 2009, 75(4):652-659.
[37]	侯俊英. 抗PLA2R抗体对特发性膜性肾病患者终末期肾病的预测价值[J]. 中国中西医结合肾病杂志, 2020, 21(1):63-65.
[38]	Rodas LM, Matas-García A, Barros X, et al. Antiphospholipase 2 receptor antibody levels to predict complete spontaneous remission in primary membranous nephropathy[J]. Clin Kidney J, 2019, 12(1):36-41. doi: 10.1093/ckj/sfy005 pmid: 30747150

抗磷脂酶A2受体抗体在原发性膜性肾病患者中的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 38

相关文章 15

编辑推荐

Metrics

本文评价

[1]	蒲武涛, 肖宜欣, 妥丽, 凯丽比努尔·马木提, 范雪婷, 崇乐. 超声造影诊断肝包虫病的系统评价和meta分析[J]. 临床荟萃, 2025, 40(3): 197-204.
[2]	李忠标, 赵习浩, 杜敏, 王江, 于跃, 张佃良. 肠腔内生性卵巢外腹膜浆液性乳头状腺癌1例并文献复习[J]. 临床荟萃, 2025, 40(3): 257-261.
[3]	季万里, 马周, 石郁喜, 孙为生. 青年脊髓硬脊膜动静脉瘘1例并文献复习[J]. 临床荟萃, 2025, 40(3): 262-265.
[4]	陈诚, 钱卓宇, 全栩毅, 段圣武. 结直肠癌浆膜及肌层受累影像诊断的研究进展[J]. 临床荟萃, 2025, 40(3): 281-284.
[5]	赵慧, 张鹏伟, 张健, 黄文辉, 李小丽, 马志刚, 金芳, 田利民. IgA为主型感染相关性肾小球肾炎伴草酸盐沉积1例及文献复习[J]. 临床荟萃, 2025, 40(2): 162-167.
[6]	申帅洁, 陈荣梯, 朱嵩, 平芬. 乳酸脱氢酶在难治性肺炎支原体肺炎中的临床应用进展[J]. 临床荟萃, 2025, 40(2): 185-188.
[7]	刘畅, 鲍晓雪, 刘辉明, 田雅玮, 李玉坤. 胰高血糖素样肽-1受体基因多态性的研究进展[J]. 临床荟萃, 2025, 40(1): 90-96.
[8]	张迎秋, 张津, 葛世豪, 陈俊敏. 成人DWI脑皮质“花边征”1例并文献复习[J]. 临床荟萃, 2024, 39(9): 821-824.
[9]	散丹, 甄瑾. 脊髓硬脊膜动静脉瘘1例并文献复习[J]. 临床荟萃, 2024, 39(9): 825-827.
[10]	郝苑苑, 王君, 黄茜. 经直肠超声联合超声造影对前列腺低回声病灶良恶性诊断的价值[J]. 临床荟萃, 2024, 39(7): 635-639.
[11]	申彤彤, 匡竞, 王玮. 血清肿瘤标志物在肝细胞癌早期诊断中的应用[J]. 临床荟萃, 2024, 39(6): 563-567.
[12]	庞樱容, 孙欣. sST2在心血管疾病中作用的研究进展[J]. 临床荟萃, 2024, 39(5): 460-465.
[13]	陈彩合, 马淑燕, 黄文辉. B淋巴细胞刺激因子及其受体在狼疮性肾炎中的研究现状[J]. 临床荟萃, 2024, 39(5): 475-480.
[14]	孙帅刚, 翟亚玲, 张文惠, 田慧娟. 扁桃体切除术治疗IgA肾病的疗效评价:一项meta分析[J]. 临床荟萃, 2024, 39(3): 197-207.
[15]	孙庆, 王海龙, 米庆, 乐暾, 牟华明. 外泌体在心力衰竭发生发展中的作用及临床价值[J]. 临床荟萃, 2024, 39(3): 259-263.